; (ii) such applications pending with the Center for Drug Evaluation and Research or the Center for Biologics Evaluation and Research that did not meet the goals for the corresponding fiscal year and the future plans of the Food and Drug Administration to meet these goals; and (iii) the most common causes within the agency for missing such goals. (B) Relevant data to determine whether the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research have met the performance enhancement goals for the corresponding fiscal year. (C) External or other circumstances impacting the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, and the Food and Drug Administration that impacted the ability of the agency to meet review time and performance enhancement goals. . (2) Issuance of corrective action reports Section 744I of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–53 ) is amended— (A) by redesignating subsections (c), (d), and (e) as subsections (d), (e), and (f), respectively